|
|
|
|
| LEADER |
01968nmm a2200421 u 4500 |
| 001 |
EB002187265 |
| 003 |
EBX01000000000000001324752 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
231108 ||| eng |
| 100 |
1 |
|
|a McDermott, David
|
| 245 |
0 |
0 |
|a Making cures more common in kidney cancer
|h Elektronische Ressource
|c David McDermott
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2023, 2023
|
| 300 |
|
|
|a 1 streaming video file (39 min.)
|b color, sound
|
| 505 |
0 |
|
|a Contents: Kidney cancer -- Immunotherapy in Renal-Cell Carcinoma (RCC) -- VHL/HIF/VEGF signaling pathway -- Development of therapies that generate remissions -- Patient focused objectives -- Tumor microenvironment -- Improving outcomes in advanced kidney cancer -- Novel therapies from translational research -- Cabozantinib, everolimus, nivolumab and relatlimab
|
| 653 |
|
|
|a Nivolumab
|
| 653 |
|
|
|a Kidneys / Cancer / Chemotherapy
|
| 653 |
|
|
|a Translational Research, Biomedical
|
| 653 |
|
|
|a Tumor Microenvironment
|
| 653 |
|
|
|a cabozantinib
|
| 653 |
|
|
|a Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
|
| 653 |
|
|
|a Von Hippel-Lindau Tumor Suppressor Protein
|
| 653 |
|
|
|a Hypoxia-Inducible Factor 1
|
| 653 |
|
|
|a Immunotherapy
|
| 653 |
|
|
|a relatlimab
|
| 653 |
|
|
|a Signal Transduction / drug effects
|
| 653 |
|
|
|a Kidney Neoplasms / immunology
|
| 653 |
|
|
|a Kidney Neoplasms / drug therapy
|
| 653 |
|
|
|a Carcinoma, Renal Cell / drug therapy
|
| 653 |
|
|
|a Everolimus
|
| 653 |
|
|
|a Kidneys / Cancer / Immunotherapy
|
| 653 |
|
|
|a Carcinoma, Renal Cell / immunology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a The biomedical & life sciences collection
|
| 500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/5464
|x Verlag
|z Streaming video file
|
| 082 |
0 |
|
|a 570
|